Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Triebel

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Blood|October 15, 1994
In vivo T-cell clonal amplification at time of acute graft-versus-host diseaseP Y Dietrich, A Caignard, A Lim, et al.
Cancer Research|March 1, 1994
Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neckA Caignard, P Y Dietrich, V Morand, et al.
Journal of the American College of Surgeons|October 1, 1995
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectumD Elias, F Farace, F Triebel, et al.
Blood|November 1, 1992
Analysis of T-cell receptor variability in transplanted patients with acute graft-versus-host diseaseP Y Dietrich, A Caignard, A Diu, et al.
International Journal of Immunopathology and Pharmacology|March 30, 2006
Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccineC M Ausiello, R Palazzo, F Spensieri, et al.
Clinical and Experimental Immunology|March 1, 2011
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primatesN Poirier, T Haudebourg, C Brignone, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 27, 1999
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosisE Angevin, L Glukhova, C Pavon, et al.
ESMO Open|September 24, 2023
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncologyS-E Al-Batran, D W Mueller, M-R Rafiyan, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Blood|October 15, 1994
In vivo T-cell clonal amplification at time of acute graft-versus-host diseaseP Y Dietrich, A Caignard, A Lim, et al.
Cancer Research|March 1, 1994
Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neckA Caignard, P Y Dietrich, V Morand, et al.
Journal of the American College of Surgeons|October 1, 1995
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectumD Elias, F Farace, F Triebel, et al.
Blood|November 1, 1992
Analysis of T-cell receptor variability in transplanted patients with acute graft-versus-host diseaseP Y Dietrich, A Caignard, A Diu, et al.
International Journal of Immunopathology and Pharmacology|March 30, 2006
Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccineC M Ausiello, R Palazzo, F Spensieri, et al.
Clinical and Experimental Immunology|March 1, 2011
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primatesN Poirier, T Haudebourg, C Brignone, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 27, 1999
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosisE Angevin, L Glukhova, C Pavon, et al.
ESMO Open|September 24, 2023
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncologyS-E Al-Batran, D W Mueller, M-R Rafiyan, et al.
Pageof 12